Nitrates: relieve ischaemic pain by unloading the heart—without causing dangerous hypotension
Nitrates are nitric-oxide donors that relax vascular smooth muscle. Their dominant haemodynamic effect at usual doses is venodilation: venous pooling lowers venous return (preload), left-ventricular wall stress and myocardial oxygen demand. They are excellent symptom-relieving anti-anginal drugs, but they do not replace urgent assessment of new chest pain or disease-modifying treatment for coronary disease.
Learning outcomes
By the end of this lesson, you should be able to explain the NO–cGMP mechanism; distinguish rapid-relief from prophylactic formulations; select a nitrate for common clinical contexts; prevent tolerance; recognise contraindications and interactions; and give safe nursing and patient counselling.
1. The essential map
| Question | High-yield answer |
|---|---|
| What are the main drugs? | Glyceryl trinitrate (GTN; nitroglycerin), isosorbide dinitrate (ISDN) and isosorbide mononitrate (ISMN). |
| Immediate effect? | Predominantly venodilation → ↓ preload → ↓ ventricular wall tension → ↓ myocardial O₂ demand. |
| Rapid relief? | Sublingual/buccal GTN or metered lingual spray for an anginal episode, using the prescribed/local emergency plan. |
| Prevention? | Longer-acting oral ISMN/ISDN, GTN patch or ointment; these do not reliably abort an attack already in progress. |
| Most dangerous interaction? | PDE-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil) and riociguat can produce profound hypotension with nitrates. |
| Classic complication of chronic exposure? | Tolerance; prevent it with a planned daily low-/nitrate-free interval appropriate to the formulation. |
2. Why angina happens—and why nitrates help
Angina is usually a mismatch between myocardial oxygen demand and oxygen supply. Tachycardia, hypertension, anaemia, fever and exertion increase demand. Fixed atherosclerotic narrowing limits flow reserve; coronary spasm can abruptly reduce supply.
Nitrates mainly correct the demand side: lower end-diastolic volume and pressure, so the ventricle does less wall work. At higher doses they also reduce arteriolar resistance (afterload). They relax large epicardial coronary arteries and can relieve vasospasm, which makes them particularly useful in vasospastic (Prinzmetal) angina. Do not oversimplify this as “nitrates open every blocked artery”: relief of pain does not exclude acute coronary syndrome.
3. Mechanism of action: NO → cGMP → smooth-muscle relaxation
Step 1: bioactivation
Organic nitrates are converted to nitric-oxide-related species in vascular smooth muscle. GTN is a prodrug, not nitric oxide itself.
Step 2: signal
NO activates soluble guanylyl cyclase, increasing cyclic GMP (cGMP).
Step 3: relaxation
cGMP-dependent signalling lowers cytosolic Ca²⁺ and favours myosin-light-chain dephosphorylation: vascular smooth muscle relaxes.
Clinical result
Veins dilate first and most: ↓ preload. With greater exposure: some arteriolar dilation, ↓ afterload and blood pressure; reflex tachycardia may occur.
Haemodynamic consequences to remember
- ↓ preload: the principal anti-anginal effect; less ventricular stretch and oxygen demand.
- ↓ afterload: more evident at higher doses; may improve forward flow but also precipitate hypotension.
- Coronary vasodilation: helps coronary spasm and redistributes flow in suitable circumstances.
- Reflex sympathetic response: dizziness, palpitations and tachycardia may counter some benefit when BP falls abruptly.
4. Drugs and formulations: match the formulation to the clinical task
| Drug/formulation | Typical role | Key teaching point |
|---|---|---|
| GTN sublingual tablet or lingual spray | Rapid treatment of an acute anginal episode; some patients use it immediately before a predictable trigger if prescribed. | Fast onset because it bypasses first-pass metabolism. Sit or lie down first. It is not a substitute for emergency evaluation of persistent/new severe pain. |
| GTN intravenous infusion | Monitored acute-care use: selected ACS, acute pulmonary oedema or hypertensive/ischaemic presentations according to protocol. | Requires continuous BP monitoring, titration and review of contraindications. Never use a fixed “one dose fits all” approach. |
| GTN transdermal patch / topical ointment | Angina prophylaxis. | Plan a daily nitrate-free interval; rotate sites and remove old patch before replacing. |
| ISDN (oral) | Angina prophylaxis; also part of the hydralazine–isosorbide dinitrate combination used in selected HFrEF patients. | Schedule deliberately to avoid continuous 24-hour nitrate exposure. |
| ISMN (oral, immediate- or extended-release) | Long-term prevention of angina. | It is not fast enough to stop an episode that has already begun. |
GTN for an acute anginal episode: a safe counselling sequence
- Stop activity and sit down (or lie down if faint); exertion and standing increase the risk of collapse.
- Use one sublingual tablet or one spray exactly as prescribed. Place a tablet under the tongue; do not chew or swallow it. Avoid food/drink until it has dissolved.
- Check whether a PDE-5 inhibitor or riociguat has been used, and do not self-administer nitrate if this interaction is possible—seek urgent clinical advice.
- If pain is severe, new, worsening, associated with breathlessness/sweating/syncope, or does not settle promptly after the initial dose, activate emergency care immediately. Follow local emergency protocol; many product directions allow repeat doses every 5 minutes up to three doses while emergency help is sought.
Clinical safety: “The pain improved with GTN” does not rule out myocardial infarction. Every first, severe, prolonged or changing chest-pain pattern needs assessment.
5. Indications: where nitrates fit
| Setting | Role of nitrates | Do not forget |
|---|---|---|
| Stable chronic angina | Rapid GTN relieves episodes; long-acting formulations reduce symptom frequency when indicated. | Also treat risk: antiplatelet/statin therapy where appropriate, BP/diabetes control, smoking cessation, exercise/rehabilitation and evaluation for revascularisation when needed. |
| Vasospastic angina | Relieve/prevent vasospasm; commonly used with calcium-channel blockers. | Identify triggers and ensure specialist assessment. |
| Acute coronary syndrome | May relieve ischaemic pain or hypertension in selected patients. | Assess BP, right-ventricular infarction/preload dependence, PDE-5 use and shock. Nitrate must never delay ECG, reperfusion decisions or emergency treatment. |
| Acute pulmonary oedema / acute HF | IV GTN may be used in selected hypertensive, congested patients under monitored protocol. | Not routine for every breathless patient; hypotension and volume status determine safety. |
| HFrEF | ISDN + hydralazine is used in selected patients when clinically indicated. | It is a defined regimen—not a reason to add nitrate alone indiscriminately. |
6. Nitrate tolerance: the exam favourite with real clinical consequences
Tolerance means loss of haemodynamic and anti-anginal effect during continuous exposure. Potential mechanisms include impaired nitrate bioactivation, oxidative stress and neurohormonal counter-regulation. A patient whose patch is worn continuously may report that it “stopped working.”
Prevention: build a daily nitrate-low/free period into the regimen. Many oral/patch schedules use roughly 10–12 hours free of nitrate exposure, while some immediate-release ISDN regimens require a longer interdose interval; follow the exact product and prescriber schedule. Do not stop abruptly or redesign the schedule independently in a patient with active angina.
Long-acting nitrate = prevention. A nitrate-free interval is planned pharmacology, not missed treatment.
7. Adverse effects: predict them from vasodilation
Very common
Throbbing headache, facial flushing and dizziness. Headache often improves with time but should be assessed if severe or atypical.
Postural hypotension
Light-headedness, weakness, blurred vision or syncope, especially when standing, dehydrated, elderly, alcohol-exposed or taking other BP-lowering drugs.
Reflex tachycardia
Palpitations and increased heart rate can occur when BP drops; this may worsen ischaemia in susceptible patients.
Uncommon but important
Marked hypotension, paradoxical worsening of angina from reflex tachycardia, skin reactions with patches, and rare methaemoglobinaemia at excessive exposure.
8. Contraindications, cautions and interactions
Never miss these
| Problem | Why it is dangerous | Action |
|---|---|---|
| PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, avanafil | Both increase cGMP signalling → potentially profound hypotension, syncope, ischaemia or shock. | Contraindicated together. Ask directly and document; observe medicine-specific washout instructions (tadalafil commonly requires at least 48 hours). |
| Riociguat (soluble guanylate-cyclase stimulator) | Excess cGMP-mediated vasodilation. | Do not combine. |
| Hypotension, shock or severe hypovolaemia | Nitrates further reduce preload/BP. | Withhold and resuscitate/evaluate according to emergency protocol. |
| Right-ventricular infarction / preload-dependent state | Cardiac output may depend on adequate RV filling. | Seek senior/acute-care guidance; avoid routine nitrate administration. |
| Severe aortic stenosis, hypertrophic obstructive cardiomyopathy | Fixed/dynamic outflow obstruction and reduced preload can cause collapse. | Specialist assessment; use great caution or avoid as directed. |
| Severe anaemia or raised intracranial pressure | May worsen oxygen delivery or cerebral haemodynamic effects. | Evaluate risk and follow product/local guidance. |
| Alcohol and other antihypertensives | Additive postural hypotension. | Counsel on slow position changes and avoiding alcohol around dosing. |
9. Nursing assessment, monitoring and patient education
Before giving a nitrate
- Assess the pain: onset, character, radiation, severity, precipitating/relieving factors; obtain ECG and urgent review where indicated.
- Record BP, pulse, oxygenation, conscious level and signs of shock/HF. A low BP is a clinical stop sign, not a number to ignore.
- Ask specifically about PDE-5 medicines, riociguat, alcohol, recent antihypertensive use and prior severe nitrate reaction.
- In suspected inferior MI, consider right-ventricular involvement and seek senior direction before reducing preload.
After giving
- Reassess pain, BP and pulse after each dose/titration. Watch closely for pallor, dizziness, collapse, headache and tachycardia.
- For IV infusion: use the prescribed pump/protocol; monitor frequently/continuously as required, and document response and adverse effects.
- For patches: remove the previous patch, rotate intact hairless skin sites, fold discarded patches safely, and maintain the prescribed patch-free interval. Avoid heat sources over a patch unless product guidance permits.
Storage and self-management
- Keep sublingual GTN in its original, tightly closed container; heat, light, moisture and transfer to another container can reduce potency. Check expiry and replacement advice.
- Carry it when prescribed, sit before use, and stand only slowly afterwards.
- Do not lend the medicine or use a friend’s “chest-pain tablet.” Tell every clinician/pharmacist about nitrate use.
10. Applied safety cases
Case 1: “He took sildenafil last night but has crushing pain now.”
Do not give GTN automatically. Treat this as an emergency chest-pain presentation, obtain urgent senior/ACS care and communicate the PDE-5 exposure. The interaction can cause catastrophic hypotension.
Case 2: “The patch no longer prevents his afternoon angina.”
First check adherence, diagnosis and triggers. Then ask whether the patch is worn continuously. Explain tolerance and escalate to the prescriber to create a safe planned nitrate-free interval; do not tell the patient to improvise the regimen.
Case 3: “A breathless patient with pulmonary oedema has BP 82/50 mmHg.”
Nitrate vasodilation can worsen perfusion. Prioritise emergency assessment, monitored resuscitation and the relevant acute-HF protocol rather than reflexively reaching for GTN.
11. Quick comparison: nitrates versus other anti-anginal classes
| Class | Main anti-anginal action | Typical limitation |
|---|---|---|
| Nitrates | ↓ preload (plus coronary/arterial dilation) | Tolerance, headache, hypotension; major PDE-5 interaction. |
| Beta blockers | ↓ heart rate, contractility and BP → ↓ O₂ demand | Bradycardia, bronchospasm risk with non-selective agents; avoid in vasospastic angina as sole treatment. |
| Calcium-channel blockers | Arterial dilation and/or rate reduction; important in vasospasm | Peripheral oedema, bradycardia/heart block with rate-limiting agents. |
| Ranolazine / other second-line options | Choice depends on phenotype and guideline/local availability | Interactions, QT issues or availability; requires individual review. |
12. High-yield revision box
- Mechanism: NO → soluble guanylyl cyclase → ↑ cGMP → smooth-muscle relaxation.
- Main haemodynamic effect: venodilation → ↓ preload → ↓ myocardial O₂ demand.
- Acute relief: sublingual/spray GTN—not ISMN extended release.
- Tolerance: prevent with a planned daily nitrate-free interval.
- Fatal viva point: nitrates + PDE-5 inhibitor/riociguat = dangerous hypotension; ask every time.
- Nursing point: sit the patient down, check BP, reassess pain and never let GTN delay emergency assessment.
References and further study
- Dimitrost Laloo. Nitrates. Supplied SlideShare teaching resource, reviewed for this curriculum lesson.
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease.
- DailyMed. Nitroglycerin sublingual tablets: prescribing information (contraindications, administration and interactions).
- DailyMed. Isosorbide dinitrate and isosorbide mononitrate: prescribing information (indications and tolerance-free dosing principles).
- European Society of Cardiology educational review: organic nitrates in medical management of angina.
Educational note: This resource supports undergraduate revision and clinical learning. Nitrate selection, route, dose and emergency management must follow the current local protocol, product information and a qualified prescriber’s plan.
